MORPHOSYS Technology definition

MORPHOSYS Technology means, individually and collectively, (a) the MORPHOSYS HuCAL GOLD Library; MORPHOSYS Anti-EST Technology; and all other software, data, and protocols, all as described in Appendix 1.36; and CONFIDENTIAL (b) any related know how and trade secrets, including but not limited to, proprietary sequence information, compositions, technology, data, techniques, specifications, designs and other information (whether or not patentable) of any type (i) existing as of the Effective Date of the Research and License Agreement (December 29, 2000) and/or during the Research Term; and (ii) in which MORPHOSYS has an ownership interest with the right to grant licenses or sublicenses thereunder, without violating the terms of any agreement or other arrangement with any third party.
View Source
MORPHOSYS Technology means MORPHOSYS Subscription Technology and MORPHOSYS Antibody Affinity Optimization Technology.
View Source
MORPHOSYS Technology means, individually and collectively, (a) the MORPHOSYS HuCAL GOLD Library; MORPHOSYS Anti-EST Technology; and all other software, data, and protocols, all as described in Appendix 1.36; and 6 of 124 ***Confidential Treatment Requested CONFIDENTIAL (b) any related know how and trade secrets, including but not limited to, proprietary sequence information, compositions, technology, data, techniques, specifications, designs and other information (whether or not patentable) of any type (i) existing as of the Effective Date of the Research and License Agreement (December 29, 2000) and/or during the Research Term; and (ii) in which MORPHOSYS has an ownership interest with the right to grant licenses or sublicenses thereunder, without violating the terms of any agreement or other arrangement with any third party.
View Source

Examples of MORPHOSYS Technology in a sentence

  • During the Term of this Agreement, each Party may disclose to the other Party proprietary information, materials and technical and business information, including but not limited to MORPHOSYS Technology, CENTOCOR Technology, HuCAL Antibody Technology (including HuCAL Antibodies), and Licensed Products (collectively, “Confidential Information”).

  • Following the agreement on such Success Criteria, (i) MORPHOSYS agrees to expend reasonable efforts to utilize MORPHOSYS Technology to generate, for CENTOCOR or its Affiliates, HuCAL Antibodies specific for the Commercial Target covered by such Commercial Therapeutic License, and (ii) CENTOCOR will expend reasonable efforts to provide MORPHOSYS with the respective Commercial Target in DNA and/or peptide/protein and/or cellular form suitable for use.

  • MORPHOSYS Technology and HuCAL Antibody Technology shall be owned by MORPHOSYS.

  • Furthermore, subject to Article 7, MORPHOSYS shall always have the right to grant to Third Parties licenses to MORPHOSYS technology (including MORPHOSYS Technology) for research purposes and commercial licenses to MORPHOSYS technology (including MORPHOSYS Technology) other than commercial therapeutic licenses.

  • MORPHOSYS and ONCOMED hereby acknowledge that, subject to Article 7, MORPHOSYS shall have the right, alone or in conjunction with a Third Party, to utilize MORPHOSYS’ technology (including MORPHOSYS Technology), and grant licenses thereunder to utilize the same, with respect to research, development and commercialization of antibodies as a therapeutic, which antibodies are directed against any Target other than a Commercial Target that is the subject of an existing exclusive Commercial Therapeutic License.

  • During the Agreement Term, each Party may disclose to the other Party proprietary information, materials and technical, business and strategic information considered as and marked “confidential”, relating to and including but not limited to MORPHOSYS Technology, Research Data, Research Inventions, Research Materials and Licensed Products (collectively, “Confidential Information”).

  • ONCOMED shall maintain records of access to and use of the MORPHOSYS Technology sufficient to enable ONCOMED and MORPHOSYS to determine, and monitor compliance with, ONCOMED’s obligations to MORPHOSYS under this Agreement.

  • In consideration of the technology and rights licensed to ONCOMED herein, ONCOMED grants to MORPHOSYS a fully paid-up, non-exclusive, irrevocable, perpetual, worldwide, royalty-free license (with the right to sublicense), under Grantback Patent Rights, for the sole purpose of allowing MORPHOSYS and/or MORPHOSYS Third Party Licensees to utilize, develop and commercialize antibodies developed through the use of MORPHOSYS’ technology (including MORPHOSYS Technology), [***] (“Grantback License”).

  • ONCOMED hereby acknowledges that the MORPHOSYS Technology at all times during the term of this Agreement and thereafter, shall remain the sole and exclusive property of MORPHOSYS.

  • ONCOMED desires to receive, and MORPHOSYS desires to grant, licenses to the MORPHOSYS Technology and resulting discoveries and products on the terms set forth herein.